Sinopharm Pharmaceutical (02096.HK) released its interim results, with a net profit of 6.04 billion yuan, a year-on-year increase of 32.2%.

Intelligent Financial News APP, Sinopharm Group (02096.HK) released its interim performance for the six months ending June 30, 2025. The group achieved a revenue of RMB 3.585 billion, a year-on-year increase of 15.14%; net profit was RMB 604 million, a year-on-year increase of 32.2%; basic earnings per share were RMB 0.25; adjusted profit attributable to equity shareholders of the company was RMB 651 million, an increase of 21.1% compared to RMB 538 million in the same period last year.